Correspondingly, eEF2K has tumor-suppressive functions in CRC, as depletion of eEF2K enhances cell survival in CRC and low expression levels of eEF2K in CRC patient tissue samples correlate with poor clinical outcome [101,102]. This evidence concerns the gene EEF2K and neoplasm.